Our method, based on a universal UDS protocol for FLT3 analysis, is instead applicable on a routine base in the AML molecular diagnostic setting, leading to a great advance in the baseline screening of FLT3 mutational status in terms of sensitivity. Here, FLT3 is linked to acute myeloid leukemia.